Opus Genetics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
None.
OPUS GENETICS, INC.
| ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---|
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 120 |
|---|---|
| Consolidated Balance Sheets | 121 |
| Consolidated Statements of Comprehensive Loss | 122 |
| Consolidated Statements of Changes in Series A Preferred Stock and Stockholders’ Equity | 123 |
| Consolidated Statements of Cash Flows | 124 |
| Notes to Consolidated Financial Statements | 125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.